Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2015
Filed with the SEC on Aug 10, 2015 and accepted by EDGAR at Aug 10, 2015, 16:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-04-01 to 2015-06-30 | $2.2m | us-gaap:Revenues |
| Revenue | 6 months2015-01-01 to 2015-06-30 | $2.7m | us-gaap:Revenues |
| Research and development | 3 months2015-04-01 to 2015-06-30 | $26.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2015-01-01 to 2015-06-30 | $51.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-04-01 to 2015-06-30 | −$32.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2015-01-01 to 2015-06-30 | −$63.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2015-04-01 to 2015-06-30 | −$32.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2015-01-01 to 2015-06-30 | −$62.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2015-04-01 to 2015-06-30 | −$0.33 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2015-01-01 to 2015-06-30 | $0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2015-01-01 to 2015-06-30 | −$57.4m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months2015-01-01 to 2015-06-30 | $3.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-06-30 | $81.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-06-30 | $339.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-06-30 | $383.2m | us-gaap:Assets |
| Current liabilities | At period end2015-06-30 | $26.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-06-30 | $37.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-06-30 | $345.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-15-058233. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.